Patients Data N (%)
Number of patients 35 (100)
Platinum+pemetrexed 18 (51.4)
Platinum+gemcitabina 17 (48.6)
Clinical Benefit
Yes 24 (68.6)
No 9 (26.5)
Unknown 2 (5.9)
Toxicity (GR3-4)
Anemia 0 (0)
Neutropenia 1 (2.9)
Thrombocytopenia 0 (0)
Rensponse to the first line
Complete response 1 (2,9)
Partial response 10(28.6)
Stationarity of disease 13 (37.1)
Progression of disease 11 (31.4)
First line chemotherapy 25 (71.4)
Pemetrexed 1 (4)
Docetaxel 0 (0)
Erlotinib 24 (96)
Other 0 (0)
Clinical Benefit
Yes 6 (24)
No 14 (56)
Unknown 5(20)
Toxicity (GR3-4)
Anemia 1 (0,9)
Neutropenia 1 (0,9)
Thrombocytopenia 1 (0,9)
Response to the second line
Complete Response 0 (0)
Partial Response 5 (20)
Stationarity of Disease 5 (20)
Progression of Disease 14 (60)
Table 2: First and second line chemotherapy characteristics and toxicity.